Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- treatment


1Medizinische Fakultaet Mannheim, University of Heidelberg, Mannheim, Germany; 2Oregon Health and Science University Cancer Institute, Portland; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Centre Hospitalier Universitaire (CHU) La La Milétri, Poitiers, France; 5Karmanos Cancer Institute, Detroit, MI; 6Department of Leukemia, The University of… (More)


10 Figures and Tables